New Lipopeptide Platform for Delivering Peptides and Proteins Into Cells | Research

The takeaway

Novel peptide gemini surfactants with lysine-based sequences outperform the established R8 cell-penetrating peptide in delivering therapeutic peptides to the cytoplasm.

6.2 μM EC50
DKCK12-K3 carrier ability for cytosolic peptide delivery, outperforming the established R8 CPP

What the researchers found

CP-PGs with tri-lysine sequences (DKCK12-K3 and DKCK12-K5) showed lower cytotoxicity and superior peptide delivery compared to the well-established R8 cell-penetrating peptide.

Why it matters

Getting therapeutic peptides inside cells remains a major drug delivery challenge. These new carriers achieve better delivery than established CPPs while maintaining low toxicity.

The numbers in context

EC50: 5.8-6.2 µM (best) vs 6.8 µM (R8); IC50: 198-241 µM (K3) vs 88 µM (R3); two C12 chains

How the study worked

Peptide synthesis, cytotoxicity assays on NIH3T3 cells, proapoptotic peptide (PAD) delivery assays measuring cell death as a functional readout of cytosolic delivery.

Who was studied

NIH3T3 cells (in vitro screening)

What this study cannot tell us

In vitro only using a single cell line. Functional readout based on apoptotic activity rather than direct delivery measurement. No in vivo data.

How to read the evidence

In vitro proof-of-concept comparing new carriers to an established standard. Early-stage but with quantitative performance data.

When this study was published

Published in 2020. Cell-penetrating peptide research continues to advance with new delivery platforms.

The bigger picture

This PG-surfactant molecular framework offers a new platform for designing cell-penetrating carriers, expanding the toolkit for intracellular peptide and protein drug delivery.

Questions still open

Do CP-PGs maintain their carrier ability in vivo?
Can this platform deliver larger proteins effectively?
How does delivery efficiency compare across different cell types?

Common questions

Why is getting peptides into cells so difficult?

Cell membranes act as barriers that prevent most peptides from entering. Peptide drugs often need to reach targets inside cells but can't cross the membrane on their own. Cell-penetrating agents like these CP-PGs help shuttle therapeutic peptides across the membrane.

What makes these new carriers better?

The CP-PG carriers combine two alkyl chains with cationic peptide sequences in a unique architecture. The best variants delivered a therapeutic peptide more efficiently than the well-established R8 peptide while causing less cell damage.

Read the original research

Development of Cell-Penetration PG-Surfactants and Its Application in External Peptide Delivery to Cytosol.

Bioconjugate chemistry, 31(3), 821-833

View on PubMed ↗Publisher’s paper ↗

Citation

Sumito, Natsumi; Koeda, Shuhei; Umezawa, Naoki; Inoue, Yasumichi; Tsukiji, Shinya; Higuchi, Tsunehiko; Mizuno, Toshihisa. (2020). Development of Cell-Penetration PG-Surfactants and Its Application in External Peptide Delivery to Cytosol.. Bioconjugate chemistry, 31(3), 821-833. https://doi.org/10.1021/acs.bioconjchem.9b00877